CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's diseaseRichard Dubinsky
Department of Neurology, University of Kansas Medical Center, Kansas City, 66160, USA
Mov Disord 21:530-3. 2006
..We conclude that, at a dose of 20 mg/kg per day, cysteamine was tolerable in people with Huntington's disease. Nausea and motoric impairment were the dose-limiting side effects...
- Mortality of stroke patients treated with thrombolysis: analysis of nationwide inpatient sample
Richard Dubinsky
University of Kansas Medical Center, Department of Neurology, Kansas City, KS 66160, USA
Neurology 66:1742-4. 2006
..1% vs 5.8%) as was the rate of secondary intracranial hemorrhage (4.2% vs 0.4%). US community experience in the use of thrombolysis has higher rates of complications and mortality than in controlled clinical trials...
- Trends in hospital utilization and outcome for patients with ALS: analysis of a large U.S. cohort
Richard Dubinsky
Department of Neurology, University of Kansas Medical Center, Mail Stop 2012, 3599 Rainbow Blvd, Kansas City, KS 66160, USA
Neurology 67:777-80. 2006
..To examine hospital mortality, utilization, and trends in care of patients with ALS in a large U.S. cohort...
- Mortality from combined carotid endarterectomy and coronary artery bypass surgery in the US
Richard M Dubinsky
Department of Neurology, University of Kansas Medical Center, Kansas City, KS 66160, USA
Neurology 68:195-7. 2007
..38 (95% CI 1.27 to 1.50) vs CABG. With the increase in postoperative stroke and death, a randomized, controlled clinical trial of combined CEA-CABG is indicated...
- No going home for hospitalized Huntington's disease patients
Richard M Dubinsky
Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas 66160, USA
Mov Disord 20:1316-22. 2005
..With 60.31% of the discharges representing new LTCF admissions, this finding shows that there is no going home from the hospital for people with HD...
